Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2016

View Archived Issues

ReNeuron awarded grant to develop stem cell-derived exosomes

Novartis and Surface Oncology to develop therapeutics targeting the tumor micro-environment

Healios gains Japanese rights to Athersys's MultiStem

IBT receives approval to start clinical trials of necrotizing enterocolitis candidate

Strategic partnership begins between Zymeworks and Kairos Therapeutics

New NCCN grants support trials of volasertib in hematologic malignancies

Phase I results indicate potential of TNT-009 in complement-mediated orphan diseases

Incyte and AstraZeneca to collaborate on INCB-39110/osimertinib combination in NSCLC

Roche to acquire Tensha Therapeutics

Juno Therapeutics acquires AbVitro

Celgene exercises right to license Lycera's ex vivo ROR-gamma agonists

Bamboo Therapeutics advances development of gene therapy for DMD

Advinus and Takeda reach third milestone in drug discovery alliance

Bellicum seeks NIH RAC approval to start clinical trials of TCR therapies

Abeona receives initial clearance for clinical trials of Sanfilippo syndrome gene therapies

Tracleer dispersible tablets launched for pediatric use in Japan

Chugai and Novartis to terminate agreement regarding co-marketing of Femara

Promising results presented for Altor's novel immunotherapies in bladder cancer

Estrogen receptor agonist therapy shows favorable phase II results in prostate cancer

FDA advisory committee recommends approval of Probuphine

Gilead submits NDA for tenofovir alafenamide for chronic HBV infection

Elocta is launched in first European countries for the treatment of haemophilia A

A new national coalition aims to accelerate next generation immunotherapy in cancer

Sage Therapeutics reports NMDA receptor modulators

Bristol-Myers Squibb describes CK1 inhibitors

FDA and EMA accept filings for venetoclax in CLL

The Medicines Company starts phase II trial of ALN-PCSsc

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...